Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
Unknown status
e-GLORIA trial Protocol Review Committee
N/A
The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy
compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis,
using a randomized, open-label, parallel-group, comparative design.
The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis
Recruiting
Shinshu University
Phase 1
In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment.
However, the bone turnover markers or the bone mineral density (BMD) are not improved in some
osteoporotic patients even though they have taken BPs and alfacalcidol more than several
years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead
of BPs and Alfacalcitol.
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Recruiting
Shinshu University
Phase 2
The aim of this study is to examine the efficacy and adverse events in the following 3 groups
in Japanese osteoporosis patients after 2-year-denosumab therapy:
SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for
24 months Eldecalcitol treatment for 24 months
Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects
Completed
Wenzhou Haihe Pharmaceutical Co., Ltd.
Phase 1
A single-center, open-label, randomized, two-period, crossover study design of
pharmacokinetics and bioavailability in healthy Chinese subjects under fasting conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
